Clinical Scorecard: Retrospective Case Series on the Use of Crisaborole for Treating Trachyonychia in Pediatric Patients
At a Glance
Category
Detail
Condition
Trachyonychia
Key Mechanisms
Crisaborole is a nonsteroidal PDE4 inhibitor with anti-inflammatory activity targeting the inflammatory pathogenesis of trachyonychia and atopic dermatitis.
Target Population
Pediatric patients aged 3–12 years with trachyonychia.
Care Setting
Department of Dermatology, Beijing Children's Hospital.
Key Highlights
Crisaborole applied twice daily led to significant clinical improvement in 82.1% of nails at week 6.
At week 12, 48.5% of nails maintained complete remission.
No severe adverse events were reported during the study.
Guideline-Based Recommendations
Diagnosis
Clinical diagnosis based on characteristic features and onychoscopic findings.
Management
Topical crisaborole is recommended for symptomatic relief in pediatric trachyonychia.
Monitoring & Follow-up
Outcomes assessed at 6 and 12 weeks using PGA and FDLQI.
Risks
Prolonged use of super-potent topical corticosteroids carries risks of local cutaneous adverse events.
Patient & Prescribing Data
Thirteen children diagnosed with trachyonychia, predominantly treatment-naïve.
Crisaborole showed favorable compliance and effectiveness in this cohort.
Clinical Best Practices
Consider crisaborole as a first-line topical treatment for pediatric trachyonychia.
Monitor for concurrent systemic or allergic conditions in affected children.
